Loading clinical trials...
Loading clinical trials...
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Whitehawk Therapeutics, Inc.
Collaborators
NCT07669948 · Procedural Pain, Pain-related Fear
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more
NCT06989112 · Endometrial Cancer
NCT07457567 · Live Face Processing in Typically Developed Participants
NCT07044336 · Endometrial Cancer, Malignant Solid Tumour
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas
START - Los Angeles
Los Angeles, California
SCRI - Florida Cancer Specialists
Sarasota, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions